Meeting
2016 Gastrointestinal Cancers Symposium
Real world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in Mexico.
Authors
Kyla Jones
T.I. Salud, Mexico City, Mexico
Kyla Jones , JUAN ALEJANDRO SILVA , Diego Novick , Brenda S Botello , Bárbara Monroy Cruz , JM Iglesias-Chiesa , Miguel Quintana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 143)
DOI
10.1200/jco.2016.34.4_suppl.143
Abstract #
143
Poster Bd #
M13
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Real-world treatment patterns of previously treated advanced gastric and gastroesophageal junction adenocarcinoma (GC) in the United Kingdom (UK).
First Author: Astra M. Liepa
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Number needed to treat (NNT) analysis of patients in CheckMate 649 (CM 649): Nivolumab plus chemotherapy versus chemotherapy as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJ/EAC).
First Author: Ryan Sugarman
Poster
2021 ASCO Annual Meeting
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Keun Wook Lee
Poster
2020 ASCO Virtual Scientific Program
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Do-Youn Oh